Switch to
More onapp

How to use scorecard? Learn more

Trident Lifeline Ltd

TLL
Pharmaceuticals
SmallcapWith a market cap of ₹183 cr, stock is ranked 2,276
High RiskStock is 6.88x as volatile as Nifty
160.005.00 (-3.03%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

Avg

Average profitability - not good, not bad

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Pharmaceuticals
SmallcapWith a market cap of ₹183 cr, stock is ranked 2,276
High RiskStock is 6.88x as volatile as Nifty

Key MetricsEdit

No LabelNo Label
25.91
PB RatioPB Ratio
4.03
Dividend YieldDiv. Yield
Sector PESector PE
-43.33
Sector PBSector PB
1.44
Sector Div YldSctr Div Yld
0.17%

Forecast & RatingsDetailed Forecast 

Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Trident Lifeline Limited is engaged in the pharmaceutical business ethical marketing in domestic as well as international market. The Company is also engaged in distribution of pharmaceutical products through a third party distribution network. It offers a range of pharmaceutical formulations and products manufactured on contract manufacturing under loan license. It deals in capsules, tablets, liquid ointment, gel, ice gel, mouthwash, paste, solution, suspension, dry powders and toothpaste. Its product portfolio includes a range of drugs like Anti-Bacterial, Anti Diarrheal, Anti-Fungal, Anti-Malarial, Anti Diabetic, Dental Cure, Proton Pump Inhibitor, Anti Protozoal, Anti Histamine, Anti-Hypertensive drugs, Anti Lipidemic Drug, Anti Parasitic, Multivitamin, Multimineral Nutraceutical and Non-steroidal anti-inflammatory drug (NSAIDS). Its product portfolio consists of approximately 832 products. It operates in India, as well as African, Latin American and East Indian countries.

Investor PresentationView older 

May 6, 2023

PDF
View Older Presentations

Financial TrendFinancial statements 

2022202322.3732.853.946.01
Revenue
Profit
All values in ₹ cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent NewsAll news 

Hmm, looks like data is unavailable here. Please come back after some time
See all news

Recent EventsAll events 

Hmm, looks like data is unavailable here. Please come back after some time
See all events